[Perspectives] Investigators' response

In the PORTEC-3 trial, adjuvant chemotherapy given during and after radiotherapy improved failure-free survival (FFS) in women with high-risk endometrial cancer, compared with radiotherapy alone. Overall survival was higher than expected at the time of trial design and the higher overall survival observed with chemoradiotherapy did not reach significance. We agree that analysis of overall survival with a longer follow-up is warranted in the PORTEC-3 trial.

https://ift.tt/2Jrj0Ti